Luzerner Kantonsspital

Running trials

• Recruiting

  Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07149649· Phase 2/3· Source

• Recruiting

  Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors

  NCT07829081· Source

• Not yet recruiting

  FAPI PET Imaging - An Exploratory Study

  NCT07705074· Phase 1/2· Source

• Recruiting

  Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)

  NCT07365423· Phase 2· Source

• Enrolling by invitation

  Comparison of Blended Care Outpatient Neurorehabilitation With Traditional Outpatient Neurorehabilitation

  NCT07458308· Source

• Recruiting

  Hypnosis and Attention in Patients With a Neurological Disease (Stroke, Traumatic Brain Injury and Multiple Sclerosis)

  NCT07256704· Source

• Recruiting

  Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial

  NCT07263438· Phase 2· Source

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Source

• Recruiting

  T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer

  NCT07581496· Source

• Recruiting

  A Space-expanding Shield in Decompressive Hemicraniectomy for Stroke

  NCT06638385· Source

• Recruiting

  Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer

  NCT07617610· Source

• Recruiting

  Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

  NCT05815927· Phase 3· Source

• Enrolling by invitation

  A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

  NCT07055607· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Source

• Recruiting

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· Phase 4· Source

• Active, not recruiting

  REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure

  NCT06557798· Source

• Recruiting

  Skin Cancer and Hyperthermia and Radiotherapy

  NCT06384053· Source

• Recruiting

  Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06401980· Phase 2· Source

• Recruiting

  Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy

  NCT05976685· Source

• Recruiting

  Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

  NCT06114108· Source

• Recruiting

  New Interactive Sensor-home-based Hand Training to Improve Dexterity

  NCT06062693· Source

• Active, not recruiting

  Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients

  NCT05705973· Source

• Active, not recruiting

  Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

  NCT04630730· Phase 2· Source

• Recruiting

  A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

  NCT05384626· Phase 1/2· Source

• Active, not recruiting

  A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

  NCT04965493· Phase 3· Source

• Active, not recruiting

  Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

  NCT04763200· Source

• Active, not recruiting

  Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

  NCT04608318· Phase 3· Source

• Recruiting

  MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

  NCT04111978· Phase 3· Source

• Active, not recruiting

  Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial

  NCT03947619· Source

• Recruiting

  Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care

  NCT04300257· Source

• Recruiting

  CARDSUP - SWISS Circulatory Support Registry

  NCT04117230· Source

• Recruiting

  Swiss Primary Biliary Cholangitis Cohort Study

  NCT03146910· Source

• Active, not recruiting

  Prostate Cancer Biobank

  NCT04024475· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke6 recruiting
• Lung cancer5 recruiting
• Prostate cancer3 recruiting
• Bladder cancer2 recruiting
• Childhood cancers2 recruiting
• Colorectal cancer2 recruiting
• Gastric and esophageal cancer2 recruiting
• Head and neck cancer2 recruiting
• Multiple sclerosis2 recruiting
• Obesity2 recruiting
• Atrial fibrillation1 recruiting
• Endometriosis1 recruiting
• Glioblastoma1 recruiting
• Heart failure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Mesothelioma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Parkinson disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Sarcoma1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

  NCT07357766· Phase 3· Source

• Completed

  SpinChip Hs-cTnI Clinical Diagnostic Performance

  NCT06499519· Source

• Completed

  Emp-Activity: Empagliflozin Functional Capacity

  NCT05350202· Source

• Completed

  Neurostatus-SMARTCARE in Comparison to Standard Neurostatus-EDSS®

  NCT05575843· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

  NCT05259033· Phase 3· Source

• Completed

  A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

  NCT06734117· Source

• Terminated

  External Validation of Two Prediction Models for Independent Gait After Stroke

  NCT05039047· Source

• Completed

  Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

  NCT04864795· Source

• Completed

  Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study

  NCT06830408· Source

• Completed

  BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

  NCT03762018· Phase 3· Source

• Terminated

  Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

  NCT03708003· Phase 2· Source

• Completed

  Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

  NCT03048825· Phase 3· Source

• Completed

  Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

  NCT03297593· Phase 2· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· Source

• Completed

  Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

  NCT02572843· Phase 2· Source

• Terminated

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· Phase 3· Source

• Completed

  ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

  NCT02078427· Source